▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Global pharmaceutical giant Bristol-Myers Squibb is set to take over US-based Celgene for a record-breaking US$74 billion, according to a Bloomberg report on Dec. 4. BMS has valued C...
[THE INVESTOR] Celltrion Healthcare, an affiliate of one of Korea’s leading biopharmaceutical firms, said on Jan. 3 that the market share of its biosimilar drug Truxima surpassed 35 percent in Europ...
[THE INVESTOR] Popular Korean actress Lee Young-ae has joined a consortium to acquire Cheil General Hospital in Seoul, the first women-specific medical institution which has been virtually closed du...
[THE INVESTOR] Korean biopharmaceutical firm Celltrion said on Jan. 2 that it has registered patents for its autoimmune disease therapeutic antibody biosimilar in over 90 countries. Remsima SC -...
[THE INVESTOR] Hanmi Pharmaceutical said on Dec.28 it has sought approval from the US Food and Drug Administration for Rolontis, its biologic drug for management of chemotherapy-induced neutropenia...
[THE INVESTOR] GC Pharma announced on Dec. 17 it has won approval from the local public health authority to carry out clinical tests on a drug that can be used to treat hemophilia. The drug comp...
[THE INVESTOR] The Korean market operator’s decision to delist a local pharmaceuticals company is raising questions about the fairness in authorities’ action against firms accused of accounting erro...
[THE INVESTOR] Samsung Bioepis’ Imraldi, a biosimilar for Humira, has earned more than 60 percent of the market in Germany, solidifying its landing in the European market, industry data indicated on...
[THE INVESTOR] The Korea Exchange, the operator of the nation’s equity market, seeks to review this week the accounting misconduct of the country’s second-largest biotech company by market cap, whic...
[THE INVESTOR] Samsung BioLogics said on Dec. 5 it has signed a contract with Saint-Gobain for supply of single-use biopharmaceutical manufacturing equipment. Under the deal, the French firm will s...
[THE INVESTOR] Korean biotech firm Hugel said on Dec. 4 that its botulinum toxin Botulax has received marketing approval from Taiwan’s Ministry of Health and Welfare. Shares of Hugel rose 3.85 perc...
[THE INVESTOR ] Celltrion said on Dec. 2 that the European Medicines Agency has accepted its application for marketing authorization to a subcutaneous version of Remsima, its biosimilar of autoimmun...
[THE INVESTOR] Samsung BioLogics CEO Kim Tae-han reaffirmed key shareholders on Nov. 30 that the company’s accounting practice was legitimate, seeking a court injunction to nullify disciplinary acti...
[THE INVESTOR] Celltrion said on Nov. 29 it has obtained marketing authorization from the US Food and Drug Administration for Truxima, its copy version of Roche’s Rituxan (rituximab), to treat non-H...
[THE INVESTOR] Samsung BioLogics said on Nov. 28 it has filed an administrative lawsuit against a recent ruling by the country‘s financial regulator that the company violated accounting rules. T...
European nations pitch to attract Korean startups at EXIT Daejeon 2019
Exit Daejeon 2019 ingrains international mindset in Korean startups
Startup CEOs pitch at DAEJEON 2019 forum
VCs, accelerators and entrepreneurs share insights on startup ecosystem
Finding right people is key to growth of startups: Slush founder
Global startup community leaders take Daejeon by storm
'Foldable display ready for commercialization': LGD CTO
MSCI appoints Tay Kim as chief of Korean unit
May 23, 2019
